Status:
COMPLETED
Reducing the Duration of Untreated Psychosis in the United States
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
First Episode Psychosis (FEP)
At Risk Mental State (ARMS)
Eligibility:
All Genders
12-30 years
Brief Summary
The goal of this project is to investigate whether a systematic screening approach for individuals with first episode psychosis (FEP) can substantially reduce Duration of Untreated Psychosis (DUP). Th...
Detailed Description
Psychosis typically emerges in late adolescence or early adulthood, during a vital stage in social and cognitive development, which can have a profoundly adverse impact on an individual's long-term fu...
Eligibility Criteria
Inclusion
- age 12- 30
- ability to participate in assessments in English
- ability to provide informed consent (assent for those under age 18)
- meet criteria for psychosis or psychosis risk on SIPS
Exclusion
- previous diagnosis of schizophrenia or schizoaffective disorder.
Key Trial Info
Start Date :
February 19 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 15 2021
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT03369730
Start Date
February 19 2018
End Date
September 15 2021
Last Update
December 14 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Trustees of Boston University
Boston, Massachusetts, United States, 02215
2
Research Foundation/City University of New York (CUNY) on behalf of CUNY Graduate School
New York, New York, United States, 10027
3
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029